Shandong Wohua Pharmaceutical Co (SZSE:002107) ROCE % : 5.01% (As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Shandong Wohua Pharmaceutical Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Shandong Wohua Pharmaceutical Co's annualized ROCE % for the quarter that ended in Mar. 2024 was 5.01%.

Shandong Wohua Pharmaceutical Co ROCE % Historical Data

The historical data trend for Shandong Wohua Pharmaceutical Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shandong Wohua Pharmaceutical Co ROCE % Chart

Shandong Wohua Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

15.05

25.84

20.45

12.49

6.54

Shandong Wohua Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															12.22	2.94	7.91	3.00	5.01

Shandong Wohua Pharmaceutical Co ROCE % Calculation

Shandong Wohua Pharmaceutical Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	54.674	/	( ( (1099.991 - 283.445)	+	(1144.706 - 287.991) )	/ 2 )
	=	54.674	/	( (816.546	+	856.715)	/ 2 )
	=	54.674	/	836.6305
	=	6.54 %

Shandong Wohua Pharmaceutical Co's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	43.108	/	( ( (1144.706 - 287.991)	+	(1161.752 - 297.226) )	/ 2 )
	=	43.108	/	( ( 856.715	+	864.526 )	/ 2 )
	=	43.108	/	860.6205
	=	5.01 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Shandong Wohua Pharmaceutical Co (SZSE:002107) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Shandong Wohua Pharmaceutical Co ROCE % Related Terms

Thank you for viewing the detailed overview of Shandong Wohua Pharmaceutical Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Shandong Wohua Pharmaceutical Co (SZSE:002107) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shandong Wohua Pharmaceutical Co Ltd (SZSE:002107) » Definitions » ROCE %

Traded in Other Exchanges

N/A

Address

Fushou East Street, Chuangye Building, 2F, New and High-Tech Industrial Development Zone, Huaifang, Shandong, CHN, 261011

Website

http://www.wohua.cn

Shandong Wohua Pharmaceutical Co Ltd is a China-based company specializing in the field of cardio-cerebral vascular medicine. The company's main products consist of Xinkeshu tablets for the treatment of coronary heart disease; Naoxueshu oral liquid, promoting blood circulation by removing blood stasis; Hupo Xiaoshi granules for the treatment of urethral calculus, and Yuandu granules for the treatment of influenza, among others.

Executives

Zhao Jun	Director
Liu Wen Yi	Supervisors
Zhang Fa Zhong	Supervisors
Zhang Ge	Director
Ma Xing Chen	Supervisors
Tian Kai Ji	Directors, executives
Kong Xian Jun	Supervisors

Shandong Wohua Pharmaceutical Co (SZSE:002107) Headlines

No Headlines